Followers | 7 |
Posts | 1577 |
Boards Moderated | 0 |
Alias Born | 02/27/2014 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, April 29, 2015 1:57:06 PM
My expectation is that the company will sell for $170 to $195 million this year, with only q3 and q4 surpassing last year's revenue numbers.
The stock price will remain undervalued regardless....as there is no way it cannot break even and post minor profits with sales above $170 million per year, regardless of endorsements.
Revenues are under pressure because of protein spiking chatter, the complete lack of exciting and engaging communication and because BB.com is guiding traffic away from Musclepharm products towards Glanbia, Cellucor and new brands....hurting the growth in the short term.
The company has done a lot of right things, but lately it has gotten a little introvert and defensive in it's communication, which has made it drop a little bit in popularity among some customers and partners.
Right now, a realistic price target is $9.5....if Brad really delivered what was promised, hell the stock price would be $20....
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM